A randomized, active comparator-controlled, parallel-group, single-blind, multicenter, Phase III study to evaluate the efficacy, safety and ımmunogenicity of subcutaneous eporon versus epoetin alpha (Eprex) in the treatment of anemia associated with chronic renal failure in pre-dialysis patients